gabexate has been researched along with Liver Diseases in 5 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " GM was administered intravenously at a dosage of 2." | 2.72 | Evaluation of a protease inhibitor in the prevention of ischemia and reperfusion injury in hepatectomy under intermittent Pringle maneuver. ( Chun, BY; Chung, HJ; Hwang, YJ; Kim, YI; Lee, JW; Lee, YJ; Song, KE, 2006) |
| "Gabexate mesilate treatment significantly decreased the elevation of serum transaminase levels and improved liver histology 24 h after the administration of CCl4 (0." | 1.33 | Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats. ( Goto, T; Kataoka, E; Lin, JG; Mikami, K; Miura, K; Ohshima, S; Segawa, D; Shibuya, T; Watanabe, D; Watanabe, S; Yoneyama, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mikami, K | 1 |
| Goto, T | 1 |
| Miura, K | 1 |
| Ohshima, S | 1 |
| Yoneyama, K | 1 |
| Lin, JG | 1 |
| Watanabe, D | 1 |
| Segawa, D | 1 |
| Kataoka, E | 1 |
| Shibuya, T | 1 |
| Watanabe, S | 1 |
| Kim, YI | 1 |
| Chung, HJ | 1 |
| Song, KE | 1 |
| Hwang, YJ | 1 |
| Lee, JW | 1 |
| Lee, YJ | 1 |
| Chun, BY | 1 |
| Iwabuchi, S | 1 |
| Takatori, M | 1 |
| Okabe, K | 1 |
| Nagaki, M | 1 |
| Muto, Y | 1 |
| Ohnishi, H | 1 |
| Moriwaki, H | 1 |
| Tsuzuki, T | 1 |
| Toyama, K | 1 |
| Nakayasu, K | 1 |
| Iida, S | 1 |
| Ueda, M | 1 |
| Toizumi, A | 1 |
1 trial available for gabexate and Liver Diseases
| Article | Year |
|---|---|
Evaluation of a protease inhibitor in the prevention of ischemia and reperfusion injury in hepatectomy under intermittent Pringle maneuver.
Topics: Adult; Female; Gabexate; Hepatectomy; Humans; Ischemia; Liver; Liver Diseases; Male; Middle Aged; Pr | 2006 |
4 other studies available for gabexate and Liver Diseases
| Article | Year |
|---|---|
Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats.
Topics: Animals; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Disea | 2005 |
[Adequate parameters for the diagnosis of disseminated intravascular coagulation (DIC) in patients with liver diseases].
Topics: Adult; Antithrombin III; Biomarkers; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinog | 1993 |
Significance of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in the pathogenesis of fulminant hepatitis: possible involvement of serine protease in TNF-mediated liver injury.
Topics: Animals; Cells, Cultured; Complement Inactivator Proteins; DNA; Gabexate; In Vitro Techniques; Inter | 1991 |
Disseminated intravascular coagulation after hepatic resection.
Topics: Anticoagulants; Bile Ducts; Carcinoma, Hepatocellular; Disseminated Intravascular Coagulation; Fibri | 1990 |